Background Psoriasis is a chronic inflammatory disease of the skin that has a major effect on an individual's physical and mental function. The disease is associated with increased healthcare resource use and costs, therefore cost-effectiveness analysis (CEA) can be used to assist decision makers with determining which treatments are optimal within a constrained healthcare system budget. Objectives Our aim was to systematically review the current literature on the CEA of existing treatment options for psoriasis, assess the quality of these studies, and summarize the evidence on the drivers of cost effectiveness. Methods A literature search using Medical Subject Headings and keywords was performed in the MEDLINE, EMBASE and Health Technology Assessment databases, as well as the National Health Service Economic Evaluation Database; the CEA Registry was searched using keywords only. All references within the relevant review articles were examined manually. Two researchers independently determined the final articles and a third researcher resolved any discrepancies. We evaluated study quality in terms of the study perspective, effectiveness measures, cost measures, economic model, and time horizon. Any sensitivity analyses conducted in the studies were examined to identify the drivers of cost effectiveness, which included any variables leading to changes in the study conclusions.
Introduction
Psoriasis is a common chronic inflammatory disease of the skin. The prevalence of psoriasis in adults varies from 0.91 % (US) to 8.5 % (Norway) and its incidence varies from 78.9/100,000 person-years (US) to 230/100,000 person-years (Italy) [1] . Psoriasis has a major impact on patients' physical and mental function, as well as their quality of life [2] . Furthermore, psoriasis is associated with increased healthcare resource use and costs [3] .
Psoriasis mostly affects Caucasians [4] , typically with onset between the ages of 15 and 30 years and with comparable frequency among males and females [5] . Despite a wide range of treatment options, which include topical therapy, phototherapy, traditional systemic therapy, and biologic agents, psoriasis remains incurable, with relapses and remissions [6] . First-line therapies, conventionally prescribed for mild psoriasis, are topical agents such as emollients, tar, steroids, and vitamin D analogues. Secondline therapies, generally prescribed for moderate-to-severe psoriasis, include phototherapy and traditional systemic agents such as methotrexate, ciclosporin, and acitretin. Patients who fail to achieve response with, or are ineligible for, both first-and second-line therapies are prescribed biologic agents (e.g. etanercept, infliximab, ustekinumab, adalimumab), which were introduced in 2003 [6] [7] [8] .
Cost-effectiveness analysis (CEA) is widely used to assist decision makers to select the most appropriate treatments within constrained healthcare system budgets. A great number of CEAs on the various treatments available for psoriasis have been published in the medical literature in recent years. To ensure resource allocation decisions are informed by highquality evidence, it is critical to assess these economic evaluations. While several systematic reviews have been conducted on previously published CEAs [9, 10] , their focus has been on only biologic therapies [9] or subsequent treatments after failure of the first biologic [10] . There has been no comprehensive assessment of the quality of these CEAs and the key drivers of cost effectiveness (i.e. variables leading to changes in study conclusions) have not been identified. This study systematically reviewed all CEAs of psoriasis treatments, examined the quality of these studies, and summarized the evidence on drivers of cost effectiveness.
Methods

Literature Search
A systematic literature search was performed using the MEDLINE, EMBASE, and Health Technology Assessment (HTA; produced by the University of York Centre for Reviews and Dissemination) databases, as well as the National Health Service Economic Evaluation Database (NHS EED); a search of the CEA Registry was undertaken to identify all CEAs of psoriasis treatments until 13 November 2013. The NHS EED search filter [11] was applied to identify all economic evaluations in MEDLINE and EMBASE (electronic supplementary Appendix I). The keywords and Medical Subject Headings (MeSH) for psoriasis were used to capture relevant economic evaluations in all databases, with the exception of the CEA Registry, in which only keywords were used. In addition, we manually examined all references within the relevant review articles to identify potentially overlooked studies. Although no language exclusions were applied, only those published in English were included in the final review.
Eligibility Criteria
Study inclusion was determined by two researchers independently (NI and CM). During the first stage, titles and abstracts for all articles identified by the literature search were screened. Articles were excluded if the study was not pertaining to psoriasis (e.g. studies on psoriatic arthritis were excluded), psoriasis treatment, or economic evaluation, or if they were conference abstracts, letters/editorials, conference reports, errata, or book chapters. Next, the full texts of all articles deemed eligible from the previous stage were reviewed to further confirm their eligibility. At this stage, the exclusion criteria were burden-of-illness studies, cost analyses, study types other than economic evaluations, review articles, editorials or reports, or articles not written in English. Any discrepancies between the two reviewers were resolved by consensus with input from a third reviewer (WZ).
Data Extraction and Qualitative Synthesis
For each study included in the final review, data were extracted into a table. The information obtained included authors, country, study year, comparators, population characteristics, study design, time horizon, perspective, data sources, effectiveness, cost, sensitivity analysis, and study conclusions. A qualitative synthesis was performed and the studies were summarized according to different treatment types.
Quality Assessment
The quality of the cost-effectiveness studies was first independently assessed by two reviewers (NI and CM) using the Quality of Health Economic Studies (QHES) instrument developed by Chiou et al. [12] . This scheme took into consideration Drummond's Checklist and the US Public Health Service Panel on Cost-Effectiveness in Health and Medicine. Although there are other instruments that can evaluate the quality of health economic studies, such as the British Medical Journal checklist [13] , the Canadian Guidelines [14] , and the Journal of the American Medical Association (JAMA) user's guide [15, 16] , the QHES instrument was used because it is the only validated instrument [17] . Consisting of 16 questions, this instrument was designed to quickly assess the common types of health economic evaluations, including cost-effectiveness and cost-utility analyses [18] . For each question, a rating of 'yes' or 'no' was assigned by the two reviewers independently. Once again, the two reviewers discussed the discrepancies until a consensus was reached, with input from a third reviewer (WZ). The items from the QHES instrument were further clarified to promote consistency across reviewers (Table 1) . Data were presented as the proportion of articles reporting each of the 16 items. Furthermore, we provided additional details and NA not applicable (in all but five of the articles reviewed), RCT randomized controlled trial, PASI Psoriasis Area Severity Index, QALY qualityadjusted life-years, DLQI Dermatology Life Quality Index, MID minimally important difference commented more on the study perspective (QHES instrument, item 2), effectiveness measures (item 11) and their data source (item 3), cost measures (item 9), economic model (item 13), and time horizon (item 8).
Sensitivity Analysis and Drivers of Cost Effectiveness
For each article included in the final review, we examined whether a sensitivity analysis was executed. Sensitivity analyses in CEAs studies are vital in identifying the drivers of cost effectiveness because they identify which variables may potentially change the study conclusions. If a sensitivity analysis was conducted, we captured what uncertain parameter estimates and different assumptions were considered (e.g. a list and the ranges of values tested were compared to the baseline value), their detailed impact (quantitative results if applicable), their impact on the final study conclusions, and what drivers of cost effectiveness were identified. We also attempted to compare across studies to estimate how model structure and assumptions impact the final results.
Results
Literature Search
The literature search identified 2,617 abstracts-695 from MEDLINE, 1,787 from EMBASE, 120 from NHS EED and HTA, 15 from the CEA Registry, and 10 from the hand search of the references from relevant review articles ( Fig. 1 ). After the initial screening of all titles and abstracts, 500 articles were selected for full-text review. A total of 53 articles were included in the final review after excluding burden-of-illness and cost-analysis studies, noneconomic evaluation studies, reviews, editorials, reports, non-English studies, and non-downloadable articles.
Most of the studies included in the review were from North America and Europe , with one multisite study across North America and Europe [68] and one each from India [69] , Israel [70] , and Japan [71] . More than three-quarters (77.8 %) of the studies were published after 2003 in the post-biologic era.
Quality Assessment
Among the 16 questions from the QHES instrument, items 3, 4, 5, 6, 8, 9, 10, and 11 reflect the study quality, while the other eight items reflect the extent to which the model is fully reported in the publication. Over 90 % of the studies reported objectives (item 1), sources of variable estimates (item 3), methodology of data abstraction (item 7), primary outcome measures (items 10 and 11), and choice of economic model (item 13) ( Table 1) . Only five studies conducted a subgroup analysis (item 4), either based on the patients with different disease severity levels at baseline [43, 56, 59, 67] or among patients who completed the study [65] . Approximately 40 % of the studies only estimated the cost-effectiveness ratios (e.g. cost per responder) for each treatment option but did not undertake an incremental analysis of the treatment alternatives (item 6). Approximately 60 % of the CEA studies applied a time horizon that was truncated, indicating that the analytic horizon did not allow time for all relevant and important outcomes to be observed (item 8). For example, discontinuation or failure of treatment, potential adverse events, or hospitalization over time were often excluded, as they were unlikely to occur within the short time horizon adapted for the CEA. The measurement of costs (item 9) was not appropriate in approximately 40 % of the studies, either because they considered only the costs of the specific treatment options or because they disregarded the costs related to adverse events. More than 30 % did not explicitly mention the source of funding for their study (item 16), and only approximately one in four studies discussed potential biases (item 14).
Synthesis of Cost-Effectiveness Analysis Studies
A detailed summary of CEA data were extracted from the selected studies (electronic supplementary Appendix II, Table A-II) . These CEA studies were also categorized in terms of their therapy type, perspectives, effectiveness measures and sources, cost components, economic model, time horizon, and the cost-effective treatments (Table 2) . Most studies compared the cost effectiveness of biologics (n = 17) or multiple modalities (n = 17), and more than half (n = 30) employed a health system perspective (i.e. the government, national health system, third-party payer, insurer, or managed care perspective) [ Table 2 ].
The Psoriasis Area and Severity Index (PASI) and quality-adjusted life-years (QALY) were used as the effectiveness measure in 26 and 15 studies, respectively. Meta-analysis (or other methods of synthesis for efficacy evidence) was employed in 16 studies. The methods detailing how utility was measured were also described (electronic supplementary Appendix II, Table A-II) . The values or changes in utility were measured by levels of PASI response in five studies [24, 40, 51, 53, 62] . Three studies mapped the Dermatology Life Quality Index (DLQI) to European Quality of Life-5 Dimensions (EQ-5D) utilities [35, 57, 59] ; however, Woolacott et al. [67] mapped the change in DLQI associated with different PASI response categories and baseline DLQI scores to changes in EQ-5D utility. The remaining studies either estimated utility values directly from study patients [22, 26, 58] , stated utility values from previous studies were used without providing further details [43, 56] , or obtained utilities by response status defined by neither PASI nor DLQI from previous studies [60] .
The costs considered in the analyses were medication (including phototherapy when applicable) costs only (n = 9), direct healthcare costs without explicitly including adverse events (n = 21), direct costs including the costs of adverse events (n = 11), direct and indirect (e.g. absenteeism or unemployment) costs without explicitly including the costs of adverse events (n = 7), and direct and indirect costs plus the costs of adverse events (n = 5) [ Table 2 ]. Some justification for not explicitly including the cost of adverse events was provided. For example, serious adverse events are rare with the treatments of interest [24, 62] , adverse event rates are similar between comparators [35, 44] , and it is conservative not to include the cost of adverse events [57, 64, 69] . In terms of the indirect costs, only one article took account of presenteeism, which is defined as reduced productivity while working due to health problems [58] . Decision tree (n = 11), Markov model (n = 10) and the 'York' model (n = 7) developed by Woolacott et al. [67] were used by most of the studies. The CEA studies also varied in time horizon; 18 studies used a timeframe of less than 1 year, 25 studies used a period of between 1 and 3 years, and only 7 studies used a duration of over 3 years.
Some studies found multiple treatment options cost effective [54] , while some studies did not find any costeffective treatment options at all [26] . In addition, studies compared different dosage and formulations (e.g. gel vs. ointments) of the same compound [44] , or sequences of different treatments [51] . The study design, analytic methods, and comparators used were diverse across the [19, 20, 28, 36, 38, 62] studies; therefore determining a single conclusion based on the findings is difficult. Despite these variations, some of the treatment options that were found to be cost effective were adalimumab (n = 7), methotrexate (n = 6), etanercept (n = 6), infliximab (n = 5), ustekinumab (n = 4), fixed-dose calcipotriol/betamethasone (n = 4), and calcipotriol (n = 3) [ Table 2 ].
Drivers of Cost Effectiveness
Within the Study
A total of 38 studies conducted sensitivity analyses (electronic supplementary Appendix III, Table A-III) . Among these, 25 studies conducted one-and/or two-way sensitivity analysis to measure the impact on final outcomes when one or two variables were simultaneously changed while all other variables were held constant. Only one study conducted a multiway sensitivity analysis by simultaneously changing multiple variables. The remaining 12 studies conducted probabilistic sensitivity analysis, either alone or with one-, two-, or multiway sensitivity analysis. The most common, uncertain variables considered for the analysis were cost and efficacy of the treatment. Different assumptions that have an impact on the costs or outcomes were also considered in the sensitivity analysis. The main assumptions include patient compliance or adherence to treatments [49, 60] , length of treatment [31] , productivity costs [58, 62] , hospitalization for non-responders [24, 62, 67] , defining responders by PASI 90 (a 90 % reduction in the PASI score) [32] or PASI 50 (a 50 % reduction) [62] instead of PASI 75 (a 75 % reduction), a treatment-free response period [21] , responding patients withdrawing from treatment [35, 40] , reduced response upon re-treatment [59] , and disutility on intermittent therapy [62] . Furthermore, more than one time horizon was applied in some studies [23, 32, 35, 40, 46, 48, 60, 71] . We found that in 20 studies, the sensitivity analyses had no impact on the final conclusions, whereas in 14 other studies, the cost-effectiveness conclusions were affected. In the remaining four studies, the authors either did not clearly state the threshold for the final cost-effectiveness decision or present whether the sensitivity analyses impacted the final conclusions. In these studies, there is a potential effect of uncertain variables on the cost-effectiveness conclusions.
According to the 18 studies where we found a definite or potential impact of uncertain variables or assumptions on the final conclusions, the key drivers included (1) the costs of the medication or phototherapy itself, or related assumptions such as dosage, a treatment-free response period, average wholesale price, and weight and waste of excess medications [21, 24, 27, 34, 40, 43, 46, 50, 51, 61, 62, 71] ; (2) the values of efficacy measures, which include PASI response rate, DLQI response rate (a minimally important difference [MID]), clearing rate, response rate achieved in re-treatment [23, 26, 27, 34, 40, 46, 59, 61] , and the choice of efficacy measures, PASI 75 or DLQI MID [34] ; (3) utility values, which comprised of those with different disease severity levels or PASI response health states, baseline utility values, and utility ratings for side effects, or being on the waiting list [22, 26, 51, 57, 67] ; (4) hospitalization assumptions for non-responders [24, 62, 67] ; (5) considering lost productivity during hospitalization [62] ; and (6) different time horizons [40] . 
Across Studies
In order to estimate the impact of model structure or assumptions on the results, we also compared across studies to check whether any patterns emerged. For this purpose, we only focused on studies comparing the same treatments and using QALY as the effectiveness measure. Four types of comparisons were conducted by at least two studies (Table 3) , and these were found to be (1) ustekinumab 45 mg every 12 weeks versus etanercept 50 mg twice weekly for 12 weeks followed by 50 mg once weekly [35, 40] ; (2) (1) and (2) The 'York' model employed by Woolacott et al. [67] and Sizto et al. [62] identified the most cost-effective sequence of treatment options conditional on a threshold value of cost effectiveness. Lloyd et al. [59] used PASI 50 as response criterion and also mapped DLQI to utility, whereas the latter two studies used PASI 75. In the study by Woolacott et al. [67] , changes in utility were mapped by considering changes in DLQI for all levels of PASI response and a different baseline DLQI. In the study by Sizto et al. [62] , changes in utility were mapped by each level of PASI response.
For comparison (4), the optimal sequence was similar between Woolacott et al. [67] and Sizto et al. [62] , but Anis et al. [24] showed a different sequence order for efalizumab and infliximab. In addition to the utility mapping method, the assumption on withdrawal rate was a possible key driver. Due to the different perspectives these three studies applied (UK vs. US), the cost measures would be different, which may provide another explanation for the different study results.
Furthermore, Woolacott et al. [67] compared their CEA with the economic evaluations supplied by the manufacturers of etanercept (Wyeth model) and efalizumab (Serono model). They also identified the same four key drivers: model structure, responder definition, utility mapping method, and withdrawal rate assumption.
Discussion
This is the first article that searched for and reviewed the available CEA studies for all treatment options in psoriasis. We focused on assessing the quality of these studies and identifying the drivers of cost effectiveness instead of the actual cost-effectiveness outcomes. We concluded the high-quality CEA studies should apply a reasonably long time horizon, adopt a valid and comparable effectiveness measure, consider all cost items relevant to the study perspective, and conduct a sensitivity analysis to assess the uncertainty around parameter estimates. We found only a small number of the studies met these rigorous standards [22, 24, 35, 40, 43, 51, 56-59, 62, 67] .
Over 30 % of CEAs of psoriasis treatments adopted a time horizon of less than 1 year despite the fact that psoriasis is a chronic disease with negative impacts on health and quality of life. Although a long time horizon is preferred, information related to the long-term experience with various psoriasis treatments is largely lacking [10, 67] . This includes the annual dropout rates from therapy, the 'remission' period assumed between spells of intermittent treatment, the efficacy of subsequent lines of treatment, the cost and incidence of adverse events, and the risk of hospitalization [10, 67] .
A large number of these CEAs evaluated the cost per responder, and the PASI was often used to identify treatment response. Regardless of its limitations [72] and other recommendations on alternative weighting in scoring [73] , the PASI has been found to be reliable and valid [74] . Some researchers proposed using an alternative scoring system called the Psoriasis Assessment Severity Score as it is more sensitive than the PASI [75] ; however, the US FDA requires PASI scores to be reported upon evaluating the efficacy of new therapeutic modalities of psoriasis [76] . While PASI 75 is the current benchmark in reporting the primary endpoints of psoriasis trials, PASI 50 has also been found to be a clinically significant endpoint [77] . A variety of cut-offs have been used in the reviewed studies (PASI 50, PASI 75, and PASI 90). Due to having only a disease-specific outcome, such as cost per PASI 75 responder in CEAs, we could not determine the cost effectiveness of an intervention due to the lack of a commonly accepted threshold, or compare the costeffectiveness results to cost effectiveness found in other diseases. QALY has been widely used and identified as the most important effectiveness measure to employ in CEAs over the last decade or so [78] . The National Health Service in the UK uses QALY as the principal measure of health outcome as recommended by the National Institute of Health and Care Excellence [78] ; however, we found approximately three-quarters of the reviewed studies did not use this measurement. When estimating direct healthcare costs, potential adverse events were often ignored. Only one study considered adverse events as well as the impact of treatment on work productivity, which includes absenteeism and presenteeism. Previous studies [79, 80] have found psoriasis was associated with substantial work productivity loss in terms of both absenteeism and presenteeism. Furthermore, indirect costs due to productivity loss could exceed the direct healthcare costs of psoriasis treatments; thus, it has been suggested that future effectiveness and cost-effectiveness studies on new treatments should take into account the impact of the new interventions on patient productivity and corresponding economic burden [79, 80] . Both absenteeism and presenteeism were ignored in the majority of the CEA studies. This omission is primarily due to the lack of empirical data on the work productivity impact of treatments. Future studies should incorporate this measure into their cost-effectiveness study model.
Sensitivity analysis was conducted in 38 studies. In over half of these studies, we did not find any impact of the uncertain parameter estimates or assumptions of interest on the final conclusions. For studies where we found an impact, the costs related to the treatment, the values and choice of treatment efficacy measures, utility values, hospitalization for non-responders, inclusion of productivity costs, and time horizons were the key drivers for the costeffectiveness conclusions. Our findings may be subject to publication bias because studies may not be published if their results are highly sensitive to uncertain parameter estimates or assumptions. The findings resulting from comparisons across studies indicate the study results are also sensitive to model structure, responder definition, utility mapping method, and withdrawal rate assumption.
One limitation of our review is that we may have missed a few CEA studies. Several CEAs were conducted directly by manufacturers [67, [81] [82] [83] but the details were not published in the literature; therefore, they were inaccessible as our search was restricted to literature publications only. In addition, we limited the final review to studies written in English and two articles could not be downloaded because they were from the early 1990s. Despite these drawbacks, we included the majority of CEA studies currently available, which enabled us to evaluate the overall quality and identify key drivers of cost effectiveness.
Conclusions
High-quality cost-effectiveness studies are needed to inform resource use decision making for psoriasis treatments. To improve the quality, further studies should be conducted to provide evidence related to the long-term experience with different treatments and to address the uncertainty associated with the key drivers of cost effectiveness.
